

(place patient label here)

Patient Name: \_\_\_\_\_



PROVIDER ORDERS

Order Set Directions:

- > (✓) - Check orders to activate: Orders with pre-checked box  will be followed unless lined out.
- > Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made
- > Initial each page and Sign/Date/Time last page

Diagnosis: \_\_\_\_\_

Allergies with reaction type: \_\_\_\_\_

POINT STUDY PROTOCOL ORDERS

Version 3 4/5/16

Protocol: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Principal Investigator: Dennis Dietrich, MD 24 hr Cell: 788-9770 or message 455-2570

Study Coordinator: Laura Armstrong Office : 455-2583 Message: 455-2583: Cell 788-7610

Study Clinical Coordinating Center: Mary Farrant 415-502-2096

Emergency contact for eligibility and unblinding and medical monitor: 866-94POINT (866-947-6468)

Site number: 043

\_\_\_\_ Date and time of onset: \_\_\_\_\_

\_\_\_\_ ABCD2 score = \_\_\_\_\_

\_\_\_\_ NIHSS score = \_\_\_\_\_

\_\_\_\_ Patient study ID number: \_\_\_\_\_

\_\_\_\_ Study medication randomization code: \_\_\_\_\_

\_\_\_\_ Randomization form scanned to pharmacy at: 455-4980

\_\_\_\_ Pharmacy called at Pharmacy number 455-5430 to dispense stat medication to POINT study team member.

Clopidogrel 75 mg vs placebo tablets

Patient to receive 8 tablets stat.

Patient to receive aspirin: \_\_\_\_\_ mg stat.

Patient to receive 75 mg vs placebo tablets daily for 89 days and label for discharge

Aspirin 162 mg for 4 days then 81 mg daily and label for discharge

Initials \_\_\_\_\_

(place patient label here)

Patient Name: \_\_\_\_\_

Order Set Directions:

- > (✓)- Check orders to activate: Orders with pre-checked box  will be followed unless lined out.
- > Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made
- > Initial each page and Sign/Date/Time last page



PROVIDER ORDERS

---

Prohibited prohibited and discouraged medications- see list attached (contact Dr. Dietrich to discuss if clinically necessary).

On discharge schedule to be seen in follow up for POINT trial within 90 days at Advanced Neurology Specialists. Call research department at 455-2583 if needed. Study medication bottle from pharmacy (aspirin and clopidogrel/placebo) are to be given to patient upon discharge.

Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_

## U.S. POINT Prohibited Medications v8

**DISCLAIMER: During the study, additional prohibited/discouraged medications may be approved for marketing that are not on this list.**

NSAIDs		Thienopyridines	
aspirin *	Anacin, Ascriptin, Bayer, Bufferin, Ecotrin, Excedrin	clopidogrel	Plavix
choline and magnesium salicylates	CMT, Tricosal, Trilisate	prasugrel	Effient
choline salicylate	Arthropan	Ticlopidine	Ticlid
celecoxib	Celebrex	Other Antiplatelets	
diclofenac potassium	Cataflam	abciximab	Reopro
diclofenac sodium	Voltaren, Voltaren XR	cangrelor	Kengreal
diclofenac sodium with misoprostol	Arthrotec	cilostazol	Pletal
diflunisal	Dolobid	dipyridamole	Aggrenox, Permole, Persantine
etodolac	Lodine, Lodine XL	eptifibatide	Integrilin
fenoprofen calcium	Nalfon	ticagrelor	Brilinta
flurbiprofen	Ansaid	tirofiban	Aggrastat
ibuprofen	Advil, Motrin, Motrin IB, Nuprin	Thrombolytics	
indomethacin	Indocin, Indocin SR	alteplase	Activase, Cathflo Activase
ketoprofen	Actron, Orudis, Orudis KT, Oruvail	reteplase	Retavase, Retavase Half-Kit
magnesium salicylate	Arthritab, Bayer Select, Doan's Pills, Magan, Mobidin, Mobogesic	tenecteplase	TNKase
meclofenamate sodium	Meclomen	urokinase	Abbokinase; Kinlytic
mefenamic acid	Ponstel	POINT Discouraged Medications v8	
meloxicam	Mobic	Proton Pump Inhibitors	
nabumetone	Relafen	dexlansoprazole	Dexilant, Kapidex
naproxen	Naprelan, Naprosyn	esomeprazole	Nexium, Nexium 24
naproxen sodium	Aleve, Anaprox	lansoprazole	Prevacid, Prevacid 24HR, Prevpac
oxaprozin	Daypro	omeprazole	Losec, Prilosec, Zegarid
piroxicam	Feldene	pantoprazole	Protonix
rofecoxib	Vioxx	rabeprazole	AcipHex
salsalate	Amigesic, Anaflex 750, Disalcid, Marthritic, Mono-Gesic, Salflex, Salsitab	Other Discouraged Medications	
sodium salicylate	Amigesic, Azulfidine, Azulfidine Entabs, Canasa, Colazal, Dipentum, Doan's Extra Strength, Doan's Regular, Dolobid, Ecotrin, Giazo, Kaopectate, Pentasa, Pepto Bismol, Salflex, Tricosal, Trilisate	cimetidine	Tagamet
sulindac	Clinoril	etravirine	Intelence
tolmetin sodium	Tolectin	felbamate	Felbatol
valdecoxib	Bextra	fluconazole	Diflucan
Anticoagulants		fluoxetine	Prozac, Prozac Weekly, Sarafem
antithrombin	ATryn	fluvoxamine	Luvox
antithrombin III	Thrombate III	ketocanazole	Nizoral
apixaban	Eliquis	mesalamine	Apriso, Asacol, Canasa Suppository, Lialda, Pentasa, Rowasa Enema
argatroban	Argatroban	olanzapine	Symbya, Zyprexa, Zyprexa Zydis, Zyprexa Relprevv
bivalirudin	Angiomax	voriconazole	VFEND
dabigatran	Pradaxa	* Maximum daily dose of aspirin from any source is 325 mg.	

## U.S. POINT Prohibited Medications v8

### Anticoagulants (continued)

dalteparin	Fragmin
danaparoid	Orgaran
desirudin	Iprivask
edoxaban	Savaysa
enoxaparin	Lovenox
fondaparinux	Arixtra
heparin	Hep-Lock, Hep Pak CVC, Heparin Lock Flush, Heparin Sub Q (subcutaneous)
lepirudin	Refludan
rivaroxaban	Xarelto
tinzaparin	Innohep
warfarin	Coumadin, Jantoven